Impact of a clinical pharmacist consultation on enhancing knowledge and safety skills in patients with chronic inflammatory arthritis treated with biologic-disease-modifying anti-rheumatic-drugs (bDMARDs)
Authors' conclusion
This study highlights the positive impact of pharmacist consultations on enhancing knowledge and safety skills in patients with IA and treated with bDMARDs.
Study context
- Population
- Patients with chronic inflammatory arthritis (IA) treated with bDMARDs receiving pharmacist consultations at the authors' hospital
- Participants
- 99 patients
- Exposure
- BioSecure knowledge score before vs at M3, M6 and M12 after pharmacist consultation
- Outcome
- Patient knowledge: BioSecure mean score (0 worst to 100 optimal), baseline vs later time points
- Follow-up
- M3, M6 and M12
Methodological detailssingle-group, no control group
- Single-group
- No control group
Main finding
As reported in the abstract
BioSecure score (0-100)
Baseline
70.7
mean · SD 18.0
M3
80.9
mean · SD 15.5
M6
83.1
mean · SD 14.5
M12
82.5
mean · SD 14.4
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
Good knowledge level (BioSecure score >84) — M3, M6, M12 vs Baseline
P < 0.001
Patient factors associated with improved knowledge
- RAPID 3 <7.5, family status, information from community pharmacist, and low Charlson scores
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Impact of a clinical pharmacist consultation on enhancing knowledge and safety skills in patients with chronic inflammatory arthritis treated with bDMARDs. Clin Exp Rheumatol. Published 11 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →